• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

配体解构:为何某些片段结合位点保守而其他位点不保守。

Ligand deconstruction: Why some fragment binding positions are conserved and others are not.

作者信息

Kozakov Dima, Hall David R, Jehle Stefan, Luo Lingqi, Ochiana Stefan O, Jones Elizabeth V, Pollastri Michael, Allen Karen N, Whitty Adrian, Vajda Sandor

机构信息

Department of Biomedical Engineering, Boston University, Boston, MA 02215;

Acpharis Inc., Holliston, MA 01746;

出版信息

Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2585-94. doi: 10.1073/pnas.1501567112. Epub 2015 Apr 27.

DOI:10.1073/pnas.1501567112
PMID:25918377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4443342/
Abstract

Fragment-based drug discovery (FBDD) relies on the premise that the fragment binding mode will be conserved on subsequent expansion to a larger ligand. However, no general condition has been established to explain when fragment binding modes will be conserved. We show that a remarkably simple condition can be developed in terms of how fragments coincide with binding energy hot spots--regions of the protein where interactions with a ligand contribute substantial binding free energy--the locations of which can easily be determined computationally. Because a substantial fraction of the free energy of ligand binding comes from interacting with the residues in the energetically most important hot spot, a ligand moiety that sufficiently overlaps with this region will retain its location even when other parts of the ligand are removed. This hypothesis is supported by eight case studies. The condition helps identify whether a protein is suitable for FBDD, predicts the size of fragments required for screening, and determines whether a fragment hit can be extended into a higher affinity ligand. Our results show that ligand binding sites can usefully be thought of in terms of an anchor site, which is the top-ranked hot spot and dominates the free energy of binding, surrounded by a number of weaker satellite sites that confer improved affinity and selectivity for a particular ligand and that it is the intrinsic binding potential of the protein surface that determines whether it can serve as a robust binding site for a suitably optimized ligand.

摘要

基于片段的药物发现(FBDD)基于这样一个前提:片段的结合模式在随后扩展为更大的配体时将保持不变。然而,尚未确立一般条件来解释何时片段结合模式会保持不变。我们表明,可以根据片段与结合能热点(即蛋白质中与配体相互作用贡献大量结合自由能的区域,其位置可通过计算轻松确定)的重合情况来建立一个非常简单的条件。由于配体结合自由能的很大一部分来自与能量上最重要热点中的残基相互作用,即使去除配体的其他部分,与该区域充分重叠的配体部分仍将保留其位置。这一假设得到了八个案例研究的支持。该条件有助于确定一种蛋白质是否适合FBDD,预测筛选所需片段的大小,并确定命中的片段是否可以扩展为具有更高亲和力的配体。我们的结果表明,配体结合位点可以有效地根据一个锚定位点来考虑,该锚定位点是排名最高的热点,主导结合自由能,周围有一些较弱的卫星位点,这些位点赋予对特定配体更好的亲和力和选择性,并且蛋白质表面的内在结合潜力决定了它是否可以作为经过适当优化的配体的强大结合位点。

相似文献

1
Ligand deconstruction: Why some fragment binding positions are conserved and others are not.配体解构:为何某些片段结合位点保守而其他位点不保守。
Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2585-94. doi: 10.1073/pnas.1501567112. Epub 2015 Apr 27.
2
Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.基于片段药物发现的热点分析经验教训。
Trends Pharmacol Sci. 2015 Nov;36(11):724-736. doi: 10.1016/j.tips.2015.08.003. Epub 2015 Nov 1.
3
Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery.基于片段的药物发现中推动命中向先导发展的热点分析。
J Chem Inf Model. 2012 Jan 23;52(1):199-209. doi: 10.1021/ci200468p. Epub 2011 Dec 15.
4
Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.基于核磁共振的片段筛选策略——靶点固定:用于片段命中识别的TINS、STD和SPR方法比较
J Biomol Screen. 2010 Sep;15(8):978-89. doi: 10.1177/1087057110375614.
5
Post processing of protein-compound docking for fragment-based drug discovery (FBDD): in-silico structure-based drug screening and ligand-binding pose prediction.基于配体结合构象预测的蛋白质-化合物对接的后处理:片段药物发现的计算结构基药物筛选。
Curr Top Med Chem. 2010;10(6):680-94. doi: 10.2174/156802610791111452.
6
Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands.基于表面等离子体共振生物传感器的乙酰胆碱结合蛋白片段筛选,通过对烟碱型乙酰胆碱受体 α7 配体进行解构,确定配体效率热点(LE 热点)。
J Med Chem. 2010 Oct 14;53(19):7192-201. doi: 10.1021/jm100834y.
7
In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.基于片段的计算机药物发现:使用 S4MPLE 建立和验证片段至先导物的计算方案。
J Chem Inf Model. 2013 Apr 22;53(4):836-51. doi: 10.1021/ci4000163. Epub 2013 Apr 11.
8
ACFIS: a web server for fragment-based drug discovery.ACFIS:一个用于基于片段的药物发现的网络服务器。
Nucleic Acids Res. 2016 Jul 8;44(W1):W550-6. doi: 10.1093/nar/gkw393. Epub 2016 May 5.
9
Benchmark Sets for Binding Hot Spot Identification in Fragment-Based Ligand Discovery.基于片段的配体发现中结合热点识别的基准集。
J Chem Inf Model. 2020 Dec 28;60(12):6612-6623. doi: 10.1021/acs.jcim.0c00877. Epub 2020 Dec 8.
10
Lead generation and examples opinion regarding how to follow up hits.潜在客户生成以及关于如何跟进潜在客户的示例意见。
Methods Enzymol. 2011;493:383-419. doi: 10.1016/B978-0-12-381274-2.00015-7.

引用本文的文献

1
A Perspective on the Strategic Application of Deconstruction-Reconstruction in Drug Discovery.药物研发中解构-重构策略应用的视角
J Med Chem. 2025 Jun 12;68(11):10520-10539. doi: 10.1021/acs.jmedchem.5c00036. Epub 2025 May 5.
2
Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.双位点端锚聚合酶抑制剂的解构为结合能提供了见解,并为配体优化指明了关键热点。
J Med Chem. 2025 Apr 10;68(7):7263-7279. doi: 10.1021/acs.jmedchem.4c02845. Epub 2025 Mar 25.
3
E-FTMap: A Protein Structure Based Pharmacophore Identification Server for Guiding Fragment Expansion.E-FTMap:一个基于蛋白质结构的药效团识别服务器,用于指导片段扩展。
J Mol Biol. 2025 Aug 1;437(15):168956. doi: 10.1016/j.jmb.2025.168956. Epub 2025 Jan 17.
4
Binary mixtures of Vanderbilt University allosteric agonist thermolysis components act as volatile spatial repellents for malaria vector mosquitoes.范德比尔特大学变构激动剂热解成分的二元混合物可作为疟蚊的挥发性空间驱避剂。
Pest Manag Sci. 2025 Jan;81(1):185-195. doi: 10.1002/ps.8421. Epub 2024 Sep 22.
5
Expanding FTMap for Fragment-Based Identification of Pharmacophore Regions in Ligand Binding Sites.扩展 FTMap 以基于片段的方法鉴定配体结合位点中的药效基团区域。
J Chem Inf Model. 2024 Mar 25;64(6):2084-2100. doi: 10.1021/acs.jcim.3c01969. Epub 2024 Mar 8.
6
Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.剪接体 RNA 解旋酶 BRR2 中构象依赖性配体热点。
Acta Crystallogr D Struct Biol. 2023 Apr 1;79(Pt 4):304-317. doi: 10.1107/S2059798323001778. Epub 2023 Apr 28.
7
Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments.探索 PD-L1 免疫检查点胞外结构域的小分子片段。
ACS Chem Biol. 2022 Sep 16;17(9):2655-2663. doi: 10.1021/acschembio.2c00583. Epub 2022 Sep 8.
8
Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugs.低分子量化合物的表型筛选为重新利用的靶向药物提供了丰富的资源。
Front Pharmacol. 2022 Aug 8;13:917968. doi: 10.3389/fphar.2022.917968. eCollection 2022.
9
Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening.分解化合物能够重建用于基于结构的药物筛选的相互作用指纹图谱。
J Cheminform. 2022 Mar 15;14(1):17. doi: 10.1186/s13321-022-00592-w.
10
Exploring protein hotspots by optimized fragment pharmacophores.通过优化的片段药效团探索蛋白质热点。
Nat Commun. 2021 May 27;12(1):3201. doi: 10.1038/s41467-021-23443-y.

本文引用的文献

1
The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.用于确定和表征蛋白质配体结合热点的FTMap系列网络服务器。
Nat Protoc. 2015 May;10(5):733-55. doi: 10.1038/nprot.2015.043. Epub 2015 Apr 9.
2
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.用于癌症治疗临床试验的MDM2-p53蛋白-蛋白相互作用小分子抑制剂(MDM2抑制剂)。
J Med Chem. 2015 Feb 12;58(3):1038-52. doi: 10.1021/jm501092z. Epub 2014 Nov 14.
3
Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.基于结构的小分子设计与优化,这些小分子靶向冯·希佩尔-林道(VHL)E3泛素连接酶与缺氧诱导因子(HIF)α亚基之间的蛋白质-蛋白质相互作用,具有体外纳摩尔亲和力。
J Med Chem. 2014 Oct 23;57(20):8657-63. doi: 10.1021/jm5011258. Epub 2014 Oct 6.
4
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.一种Nutlin的解构:剖析一种强效蛋白质-蛋白质相互作用抑制剂的结合决定因素。
ACS Med Chem Lett. 2013 May 24;4(7):660-5. doi: 10.1021/ml400062c. eCollection 2013 Jul 11.
5
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.用一种广谱硼酸衍生物靶向 A 类和 C 类丝氨酸β-内酰胺酶。
J Med Chem. 2014 Jun 26;57(12):5449-58. doi: 10.1021/jm5006572. Epub 2014 Jun 16.
6
Structure-based efforts to optimize a non-β-lactam inhibitor of AmpC β-lactamase.基于结构的优化AmpC β-内酰胺酶非β-内酰胺抑制剂的研究工作。
Bioorg Med Chem. 2014 Jul 1;22(13):3351-9. doi: 10.1016/j.bmc.2014.04.051. Epub 2014 May 5.
7
Substrate deconstruction and the nonadditivity of enzyme recognition.底物解构与酶识别的非加和性。
J Am Chem Soc. 2014 May 21;136(20):7374-82. doi: 10.1021/ja501354q. Epub 2014 May 12.
8
Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?核磁共振片段筛选是否经过微调以评估蛋白质-蛋白质相互作用的成药潜力?
ACS Med Chem Lett. 2014 Jan 9;5(1):23-28. doi: 10.1021/ml400296c. Epub 2013 Nov 3.
9
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interface.全面的实验和计算分析 NF-κB 必需调节剂/IKKβ 蛋白-蛋白界面结合能热点。
J Am Chem Soc. 2013 Apr 24;135(16):6242-56. doi: 10.1021/ja400914z. Epub 2013 Apr 10.
10
In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3β.糖原合酶激酶-3β 的 ATP 竞争性抑制剂的计算机重构。
J Chem Inf Model. 2012 Dec 21;52(12):3233-44. doi: 10.1021/ci300355p. Epub 2012 Dec 12.